GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan New Pharm Co Ltd (XKRX:054670) » Definitions » EV-to-EBITDA

Daehan New Pharm Co (XKRX:054670) EV-to-EBITDA : 4.59 (As of Jun. 21, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Daehan New Pharm Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Daehan New Pharm Co's enterprise value is ₩116,990 Mil. Daehan New Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩25,490 Mil. Therefore, Daehan New Pharm Co's EV-to-EBITDA for today is 4.59.

The historical rank and industry rank for Daehan New Pharm Co's EV-to-EBITDA or its related term are showing as below:

XKRX:054670' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.89   Med: 19.66   Max: 1152.89
Current: 4.58

During the past 13 years, the highest EV-to-EBITDA of Daehan New Pharm Co was 1152.89. The lowest was -24.89. And the median was 19.66.

XKRX:054670's EV-to-EBITDA is ranked better than
88.01% of 709 companies
in the Drug Manufacturers industry
Industry Median: 14.15 vs XKRX:054670: 4.58

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-21), Daehan New Pharm Co's stock price is ₩7730.00. Daehan New Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩951.000. Therefore, Daehan New Pharm Co's PE Ratio for today is 8.13.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Daehan New Pharm Co EV-to-EBITDA Historical Data

The historical data trend for Daehan New Pharm Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daehan New Pharm Co EV-to-EBITDA Chart

Daehan New Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.63 -22.58 6.02 3.26 5.39

Daehan New Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 3.82 3.96 5.39 4.91

Competitive Comparison of Daehan New Pharm Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Daehan New Pharm Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daehan New Pharm Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daehan New Pharm Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Daehan New Pharm Co's EV-to-EBITDA falls into.



Daehan New Pharm Co EV-to-EBITDA Calculation

Daehan New Pharm Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=116990.457/25490.26
=4.59

Daehan New Pharm Co's current Enterprise Value is ₩116,990 Mil.
Daehan New Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩25,490 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daehan New Pharm Co  (XKRX:054670) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Daehan New Pharm Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7730.00/951.000
=8.13

Daehan New Pharm Co's share price for today is ₩7730.00.
Daehan New Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩951.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Daehan New Pharm Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Daehan New Pharm Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Daehan New Pharm Co (XKRX:054670) Business Description

Traded in Other Exchanges
N/A
Address
1062-4 Namhyeon-dong, Gwanak-gu, Seoul, KOR, 137-851
Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.

Daehan New Pharm Co (XKRX:054670) Headlines

No Headlines